Published in J Am Coll Cardiol on May 30, 2017
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Trends in heart failure incidence and survival in a community-based population. JAMA (2004) 8.90
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med (2016) 7.87
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med (1996) 4.25
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol (2008) 3.73
Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J (1999) 3.38
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation (2009) 2.34
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 2.23
Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol (2004) 1.72
Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail (2010) 1.07
Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks? Circulation (2006) 1.05
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. Eur J Heart Fail (2009) 1.03
Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. Am J Cardiol (2004) 0.99
Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart (2015) 0.95
Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation (2012) 0.93
[Italian Network on Congestive Heart Failure: ten-year experience]. G Ital Cardiol (Rome) (2006) 0.82
Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? JACC Clin Electrophysiol (2017) 0.80
Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. Heart (2015) 0.75
The Association of Mammographic Density and Molecular Breast Cancer Subtype. Cancer Epidemiol Biomarkers Prev (2017) 0.75
The Fault Is in Our Scars: LGE and Ventricular Arrhythmia Risk in LV Dysfunction. JACC Cardiovasc Imaging (2016) 0.75